DCT

3:26-cv-10378

AbbVie Inc v. Hetero USA Inc

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 3:26-cv-10378, D.N.J., 08/14/2026
  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because Defendant Hetero USA has a principal place of business in the district. For the foreign defendants, venue is asserted on the basis that they may be sued in any judicial district.
  • Core Dispute: Plaintiffs allege that Defendants' filing of an Abbreviated New Drug Application (ANDA) to market generic versions of Plaintiffs' QULIPTA® (atogepant) tablets constitutes an act of patent infringement under the Hatch-Waxman Act.
  • Technical Context: The technology involves specific methods of using the CGRP receptor antagonist atogepant for the preventive treatment of migraine in particular patient subpopulations.
  • Key Procedural History: This lawsuit is a follow-on action to a prior case filed by Plaintiffs against Hetero concerning different patents related to the same QULIPTA® product (the "First Suit"). The current complaint was filed after Plaintiffs received a "Third Notice Letter" from Hetero containing a Paragraph IV certification against the '897 patent. Plaintiffs allege they have not yet received a Paragraph IV certification for the '341 patent, suggesting this complaint serves as the initial notice for that patent.

Case Timeline

Date Event
2021-09-27 Priority Date for '897 and '341 Patents
2021-09-28 FDA Approval of QULIPTA® NDA No. 215206
2025-11-24 Hetero's First Notice Letter (related to patents in First Suit)
2026-01-07 Plaintiffs file "First Suit" against Hetero
2026-02-12 Hetero's Second Notice Letter (related to patents in First Suit)
2026-05-12 U.S. Patent No. 12,622,897 Issues
2026-06-23 U.S. Patent No. 12,661,341 Issues
2026-07-01 Plaintiffs receive Hetero's Third Notice Letter (re: '897 Patent)
2026-08-14 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,622,897 - "Methods of Treating Migraine" (Issued May 12, 2026)

The Invention Explained

  • Problem Addressed: The patent background describes migraine as a highly prevalent and disabling neurological condition for which there is a significant unmet need for effective preventive treatments Compl. ¶45 '897 Patent, col. 1:25-34
  • The Patented Solution: The patent discloses methods for the preventive treatment of migraine using the CGRP receptor antagonist atogepant, specifically focusing on its use in patients who are concurrently taking other medications that may interact with atogepant's metabolism or transport '897 Patent, col. 4:15-19 The invention identifies specific, safe, and effective dosing regimens for atogepant when co-administered with drugs known as OATP inhibitors, which can significantly increase exposure to atogepant '897 Patent, col. 5:49-col. 6:4
  • Technical Importance: This method provides a tailored dosing strategy to ensure safety and efficacy in a specific patient subpopulation, addressing the clinical challenge of drug-drug interactions (DDIs).

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '897 patent, including at least Claim 1 Compl. ¶78
  • Independent Claim 1:
    • A method for the preventive treatment of migraine in a patient
    • undergoing concurrent treatment with an OATP inhibitor,
    • the method comprising orally administering a therapeutically effective dose of 10 mg atogepant once daily to the patient,
    • wherein the patient's migraines are safely and effectively treated.
  • The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 12,661,341 - "Methods of Treating Migraine" (Issued June 23, 2026)

The Invention Explained

  • Problem Addressed: The patent addresses the need for safe and effective methods to prevent migraine in patients with pre-existing medical conditions that could affect how a drug is processed by the body, specifically hepatic (liver) impairment '341 Patent, col. 9:1-9
  • The Patented Solution: The patent provides a method for preventively treating migraine in patients with mild or moderate hepatic impairment by administering specific daily doses of atogepant '341 Patent, col. 9:10-17 The invention is based on clinical findings that determined how atogepant exposure is altered in these patients, allowing for the identification of a dosing regimen that remains safe and effective despite the compromised liver function '341 Patent, col. 9:18-24
  • Technical Importance: This invention provides a clinically validated treatment plan for a vulnerable patient population, enabling them to use atogepant for migraine prevention with a reduced risk of adverse effects related to altered drug metabolism.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '341 patent, including at least Claim 1 Compl. ¶107
  • Independent Claim 1:
    • A method for the preventive treatment of migraine in a patient having mild or moderate hepatic impairment,
    • the method comprising orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient.
  • The complaint does not explicitly reserve the right to assert dependent claims.

III. The Accused Instrumentality

Product Identification

  • The accused instrumentalities are Hetero's generic atogepant oral tablets in 10 mg, 30 mg, and 60 mg dosage forms, for which Hetero is seeking FDA approval via ANDA No. 220986 Compl. ¶1 Compl. ¶57

Functionality and Market Context

  • The complaint alleges that Hetero's generic products are intended to be generic versions of Plaintiffs' QULIPTA® Tablets Compl. ¶57 As such, they are expected to be bioequivalent to QULIPTA® and prescribed for the same indication: the preventive treatment of migraine in adults Compl. ¶44 Compl. ¶¶67-68
  • The infringement allegation centers on the proposed labeling for Hetero's generic products. The complaint alleges that this labeling will recommend or suggest the same conditions of use as the FDA-approved label for QULIPTA®, which includes specific dosage instructions for patients with hepatic impairment and for those concomitantly using OATP inhibitors Compl. ¶46 Compl. ¶68 The filing of the ANDA is alleged to be an act of infringement because it seeks approval to market the drug for these patented uses before the patents expire Compl. ¶2 Compl. ¶76 Compl. ¶105

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not contain a claim chart. The following summary is based on the narrative infringement allegations.

'897 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the preventive treatment of migraine in a patient Hetero's ANDA seeks approval for its generic atogepant products for the preventive treatment of migraine. The proposed label is alleged to contain this indication. ¶68 col. 4:35-39
undergoing concurrent treatment with an OATP inhibitor, The QULIPTA® label, which Hetero's proposed label is expected to mirror, contains a recommended dosage for patients who concomitantly use OATP inhibitors. It is alleged Hetero's label will instruct this use. ¶46; ¶80 col. 5:49-54
the method comprising orally administering a therapeutically effective dose of 10 mg atogepant once daily to the patient, Hetero's ANDA seeks approval for 10 mg tablets. The QULIPTA® label instructs a 10 mg dose for patients on OATP inhibitors, and Hetero's proposed label is alleged to instruct the same. ¶46; ¶57 col. 6:1-4
wherein the patient's migraines are safely and effectively treated. The complaint alleges Hetero's generic products will have the same safety and efficacy information as QULIPTA®, as required for ANDA approval. ¶68 col. 3:1-5

'341 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the preventive treatment of migraine in a patient having mild or moderate hepatic impairment, The QULIPTA® label includes a dosing regimen for patients with mild or moderate hepatic impairment. The complaint alleges Hetero's proposed label will instruct or recommend this use. ¶46; ¶109 col. 9:1-9
the method comprising orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient. Hetero is seeking approval for 10 mg, 30 mg, and 60 mg tablets. The QULIPTA® label recommends these doses for patients with mild or moderate hepatic impairment. It is alleged Hetero's label will instruct the same. ¶46; ¶57 col. 9:10-17
  • Identified Points of Contention:
    • Scope Questions: The core of the dispute will likely concern induced infringement. A primary question will be whether Hetero's proposed product label will actively instruct or encourage physicians and patients to use the generic product in the specific manner claimed by the patents-namely, for patients on OATP inhibitors ('897 Patent) or for patients with mild/moderate hepatic impairment ('341 Patent). The analysis will focus on whether the label language constitutes active inducement or is merely informational.
    • Technical Questions: While the case is not about direct technical operation, an evidentiary question will be what, precisely, Hetero's proposed product labeling states. As the complaint was filed before the ANDA was approved and the final label is not yet public, the allegations are based on the required similarities between a generic label and the reference listed drug's label. The ultimate infringement analysis will depend on the final text of that label.

V. Key Claim Terms for Construction

  • The Term: "concurrent treatment" ('897 Patent, Claim 1)

  • Context and Importance: This term is critical for defining the patient population covered by the '897 Patent. The scope of infringement hinges on what temporal relationship between the administration of atogepant and an OATP inhibitor qualifies as "concurrent." Practitioners may focus on this term because its definition will determine whether a patient who, for example, takes an OATP inhibitor in the morning and atogepant at night, or who takes an OATP inhibitor for a short course, falls within the claim.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The specification uses the term "concomitantly" interchangeably with "concurrently" '897 Patent, col. 4:15-19 This may support an interpretation that does not require simultaneous administration, but rather administration during the same overall treatment period.
    • Evidence for a Narrower Interpretation: The patent does not appear to provide a specific definition that would narrow the term significantly, but a defendant might argue that the context of managing DDIs implies a close temporal proximity where drug-drug interactions are most likely to occur, such as administration on the same day.

  • The Term: "mild or moderate hepatic impairment" ('341 Patent, Claim 1)

  • Context and Importance: This term defines the patient population of the '341 Patent. While the term has a recognized medical meaning, its precise scope within the context of the patent will be central to infringement.

  • Intrinsic Evidence for Interpretation:

    • Evidence for a Broader Interpretation: The patent specification does not appear to offer language that would broaden the term beyond its standard medical definition.
    • Evidence for a Narrower Interpretation: The specification explicitly defines the patient populations by referencing the Child-Pugh score: "mild hepatic impairment refers to Child-Pugh Class A; moderate hepatic impairment refers to Child-Pugh Class B" '341 Patent, col. 9:4-7 This provides strong intrinsic evidence for a specific, well-defined, and potentially narrow construction tied directly to this clinical scoring system.

VI. Other Allegations

  • Indirect Infringement: The complaint is founded on allegations of induced infringement under 35 U.S.C. § 271(b). It alleges that Hetero knows and intends for healthcare providers and patients to infringe the patents by following the instructions that will be in the proposed product labeling for its generic atogepant tablets (Compl. ¶78; Compl. ¶79; Compl. ¶80; Compl. ¶81).
  • Willful Infringement: The complaint alleges Hetero had pre-suit knowledge of the '897 patent via its Third Notice Letter, which included a Paragraph IV certification Compl. ¶79 For the '341 patent, the complaint itself provides notice Compl. ¶102 These allegations of knowledge form the basis for a potential willfulness claim should infringement be found.

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of induced infringement: does the language of Hetero's proposed (and ultimately approved) label actively instruct or encourage the patented methods of use, or does it merely provide information in a manner that falls short of inducement? This will turn on a detailed analysis of the label's text and the legal standard for inducement in the Hatch-Waxman context.
  • A key procedural question concerns the propriety of asserting the '341 patent for which Plaintiffs allegedly have not received a Paragraph IV notice. The case may explore whether the act of filing an ANDA for a drug with known indications constitutes an act of infringement for a later-issued or later-listed patent covering those indications, even without a specific certification from the ANDA filer.
  • A central question of claim scope will be whether the patented "methods of treating" a specific patient sub-population (e.g., those with hepatic impairment or on OATP inhibitors) can be infringed by a generic manufacturer who seeks a broad indication for migraine prevention, where use by the claimed sub-population is a foreseeable and intended result of marketing the drug.
Loading Complaint